SAN ANTONIO, Texas — Powerhouse Therapeutics Inc today announced that it will highlight new preclinical findings for its lead candidate, PH102, during the San Antonio Liver Cancer Symposium (SALCS), held October 11–12 at the Hilton Palacio del Rio.
PH102 is an autologous, “triple-threat” CAR T-cell therapy engineered to attack glypican-3-positive hepatocellular carcinoma through simultaneous tumor killing, immune activation, and micro-environment remodeling. Recent in vivo studies show deep, durable tumor regression without safety-limiting toxicity.
Chief Scientific Officer Gang Huang, PhD will deliver the oral presentation “CAR T-cell-based Triple-Hit Immunotherapy for Hepatocellular Carcinoma” on Friday, October 11, at 9:30 a.m. in the Liver Cancer Immunology session. Chief Executive Officer Vincent Pham will present a poster on PH102 during the symposium’s poster reception that afternoon at 3:45 p.m.
“Our data suggest PH102 can overcome key resistance pathways that limit current therapies,” said Dr. Huang. “We look forward to sharing these results with the liver cancer community.”
Mr. Pham added, “SALCS brings together leading clinicians, researchers, and industry partners. Presenting here underscores our commitment to rapid translation of PH102 into first-in-human trials.”
Hosted by the Mays Cancer Center at UT Health San Antonio, SALCS offers two days of plenary talks, panel discussions, and continuing-education programming designed to advance the prevention and treatment of liver cancers.
